General Info

DUSA Pharmaceuticals is a biopharmaceutical research and development company engaged in the development and marketing of its proprietary Levulan photodynamic and Levulan photodetection therapies for the treatment of multiple medical conditions. These products, when delivered to target tissues, are converted by fast growing cells into protoporphyrin IX, a potent photosensitizer, which can then be activated by an appropriate light source. The company s primary focus is in the area of dermatology. Both Levulan photodynamic and Levulan photodetection therapies utilize light-activated compounds to induce a therapeutic or detection effect. DUSA also markets Levulan Kerastick, a 20 percent topical solution that is part of a photodynamic therapy system to treat actinic keratoses, and BLU-U, a blue light photodynamic therapy illuminator that is intended for the treatment of nonhyperkeratotic actinic keratoses of the face or scalp. DUSA Pharmaceuticals maintains its corporate headquarters in Wilmington, Mass., and operates satellite offices in Valhalla, N.Y., and Toronto.